A naturally derived alternative treatment to quit smoking and vaping

Cytisinicline binds to the same receptors as nicotine to reduce both withdrawal symptoms and satisfaction associated with smoking and vaping.

When nicotine binds to this receptor, it causes dopamine to be released. Cytisinicline is believed to act as a partial agonist, preventing nicotine from binding and releasing dopamine.

In the Pipeline

The ORCA (Ongoing Research of Cytisinicline for Addiction) program was designed to evaluate cystisinicline’s potential as a new tool to combat nicotine dependence.